An increasing body of studies highlight the potential of IL22 as a therapeutic drug against NAFLD through the induction of antimicrobial peptides, especially of the Reg3 lectins family, and the regulation of gut microbiota. Here, IL22 is linked to metabolic dysfunction-associated steatotic liver disease.